EUVIMEDOpdag EUVIMED
Crossref

Hoehn and Yahr staging of Parkinson rsquo s disease in relation to neuropsychological measures

Edward Justin Modestino, AnnaMarie Reinhofer, Kenneth Blum, Chioma Amenechi, Patrick O'Toole

Frontiers in Bioscience · 2018 · 23 (7) · 1370-1379

DOI: 10.2741/4649 ↗

At a glance

Journal article in Frontiers in Bioscience, 2018. Written by Edward Justin Modestino and 4 co-authors. Institution: Department of Psychology, Curry College, Milton, MA USA, edward.modestino@gmail.com. Cited 36 times so far (Crossref).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Parkinson's disease (PD) is primarily considered to be a progressive degenerative motor disease associated with the degeneration of striatal dopamine neurons. However, increasing evidence has suggested progressive cognitive and psychiatric changes as well. Forty-six patients with PD, ranging in severity from Hoehn and Yahr (H-Y) score of 1:4, were recruited from a clinic specializing in PD. Various cognitive and neuropsychological measures were used to discover if there were indeed differences due to the progression of PD. As H-Y stage significantly increased, so did age and levodopa equivalency dose of medications, both independent of one another. Years of education had a significant negative relationship with H-Y score. Measures of general cognition divulged a significant decrease as H-Y score increased. Finally, as H-Y score increased, magical ideation decreased, and religious group social support increased. Mechanistically, the significant cognitive decline occurring with H-Y staging may be linked to a reduced dopaminergic function. Significant cognitive and neuropsychological changes are associated with the progression of PD and its possible relationship to Reward Deficiency Syndrome (RDS).

Subjects

MeSH terms (MEDLINE)

AdultAge FactorsAgedAged, 80 and overAntiparkinson AgentsCognitionDisease ProgressionEducational StatusFemaleHumansLevodopaLinear ModelsMaleMiddle AgedNeuropsychological TestsParkinson Disease

Substances

Antiparkinson AgentsLevodopa

Authors and institutions

  • Department of Psychology, Curry College, Milton, MA USA, edward.modestino@gmail.com.
  • Department of Neurology, Boston University School of Medicine, Boston, MA, USA.
  • Department of Psychiatry, McKnight Brain Institute, University of Florida, College of Medicine, Gainesville, FL, USA.

Cite

APA

Modestino, E. J., Reinhofer, A., Blum, K., Amenechi, C., & O'Toole, P. (2018). Hoehn and Yahr staging of Parkinson rsquo s disease in relation to neuropsychological measures. Frontiers in Bioscience, 23(7), 1370-1379. https://doi.org/10.2741/4649

Vancouver

Modestino EJ, Reinhofer A, Blum K, Amenechi C, O'Toole P. Hoehn and Yahr staging of Parkinson rsquo s disease in relation to neuropsychological measures. Frontiers in Bioscience. 2018;23(7):1370-1379. doi:10.2741/4649

BibTeX
@article{Modestino2018,
  author = {Modestino, Edward Justin and Reinhofer, AnnaMarie and Blum, Kenneth and Amenechi, Chioma and O'Toole, Patrick},
  title = {Hoehn and Yahr staging of Parkinson rsquo s disease in relation to neuropsychological measures},
  journal = {Frontiers in Bioscience},
  year = {2018},
  volume = {23},
  number = {7},
  pages = {1370--1379},
  doi = {10.2741/4649}
}
Start for free →